Literature DB >> 31668686

Factors predictive of Cutibacterium periprosthetic shoulder infections: a retrospective study of 342 prosthetic revisions.

Frederick A Matsen1, Anastasia Whitson2, Moni B Neradilek3, Paul S Pottinger4, Alexander Bertelsen2, Jason E Hsu2.   

Abstract

BACKGROUND: Cutibacterium are the most common cause of periprosthetic shoulder infections, as defined by ≥2 deep cultures. Established Cutibacterium periprosthetic infections cannot be resolved without prosthesis removal. However, the decision for implant removal must be made from an assessment of infection risk before the results of intraoperative cultures are finalized. We hypothesized that the risk for a Cutibacterium infection is associated with characteristics that are available at the time of revision arthroplasty.
METHODS: In a retrospective review of 342 patients having prosthetic revisions between 2006 and 2018 for whom definitive deep culture results were available, we used univariate and multivariate analyses to compare the preoperative and intraoperative characteristics of 101 revisions with Cutibacterium periprosthetic infections to the characteristics of 241 concurrent revisions not meeting the definition of infection.
RESULTS: Patients with definite Cutibacterium periprosthetic infections were younger (59 ± 10 vs. 64 ± 12, P < .001), were more likely to be male (91% vs. 44%, P < .001), were more likely to have had their index procedure performed for primary osteoarthritis (54% vs. 39%, P = .007), were more likely to be taking testosterone supplements (8% vs. 2%, P = .02), had lower American Society of Anesthesiologists scores (1.9 ± 0.7 vs. 2.3 ± 0.7, P < .001), and had lower body mass indices (29 ± 5 vs. 31 ± 7, P = .005). Patients with definite Cutibacterium periprosthetic infections also had significantly higher preoperative loads of Cutibacterium on their unprepared skin surface (1.7 ± 0.9 vs. 0.4 ± 0.8, P < .001) and were more likely to have the surgical finding of synovitis (41% vs. 16%, P < .001).
CONCLUSIONS: The risk of definite Cutibacterium periprosthetic infections is associated with observations that can be made before or at the time of revision arthroplasty.
Copyright © 2019 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cutibacterium; Propionibacterium; failed shoulder arthroplasty; periprosthetic infection; prosthetic revision

Mesh:

Substances:

Year:  2019        PMID: 31668686     DOI: 10.1016/j.jse.2019.08.008

Source DB:  PubMed          Journal:  J Shoulder Elbow Surg        ISSN: 1058-2746            Impact factor:   3.019


  4 in total

1.  Factors associated with failure of surgical revision and IV antibiotics to resolve Cutibacterium periprosthetic infection of the shoulder.

Authors:  Corey J Schiffman; Zachary D Mills; Jason E Hsu; Anastasia J Whitson; Frederick A Matsen Iii
Journal:  Int Orthop       Date:  2022-01-15       Impact factor: 3.075

2.  Prosthetic Shoulder Joint Infection by Cutibacterium acnes: Does Rifampin Improve Prognosis? A Retrospective, Multicenter, Observational Study.

Authors:  Helem H Vilchez; Rosa Escudero-Sanchez; Marta Fernandez-Sampedro; Oscar Murillo; Álvaro Auñón; Dolors Rodríguez-Pardo; Alfredo Jover-Sáenz; Mª Dolores Del Toro; Alicia Rico; Luis Falgueras; Julia Praena-Segovia; Laura Guío; José A Iribarren; Jaime Lora-Tamayo; Natividad Benito; Laura Morata; Antonio Ramirez; Melchor Riera
Journal:  Antibiotics (Basel)       Date:  2021-04-21

3.  Preoperative Skin Cultures Predict Periprosthetic Infections in Revised Shoulder Arthroplasties: A Preliminary Report.

Authors:  Frederick A Matsen; Anastasia Whitson; Jason E Hsu
Journal:  JB JS Open Access       Date:  2020-11-25

4.  Association Between Serum Testosterone Levels and Cutibacterium Skin Load in Patients Undergoing Elective Shoulder Arthroplasty: A Cohort Study.

Authors:  Corey J Schiffman; Jason E Hsu; Kevin J Khoo; Anastasia Whitson; Jie J Yao; John C Wu; Frederick A Matsen
Journal:  JB JS Open Access       Date:  2021-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.